Clinical Trials Logo
  1. Home
  2. Nasolabial Folds
  3. NCT02647853

Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers

Lipodystrophy Clinical Trial

Official title:
A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel

Clinical Trial Summary

This Phase 1, randomized, placebo-controlled, double-blind, healthy volunteer study tested the safety, tolerability, and plasma pharmacokinetics of two different concentrations of TAT4 Gel administered once daily to 50 cm2 of skin for 14 days.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02647853
Study type Interventional
Source Topokine Therapeutics, Inc.
Contact
Status Completed
Phase Phase 1
Start date October 2014
Completion date December 2014
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05419037 - Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Recruiting NCT03059121 - The Cleveland Cardiometabolic Cohort
Completed NCT00656175 - Raltegravir Therapy for Women With HIV and Fat Accumulation Phase 2
Completed NCT00006185 - Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Phase 1
Completed NCT00202241 - The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS N/A
Recruiting NCT02262832 - Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Phase 3
Completed NCT01679197 - Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Phase 2
Active, not recruiting NCT00715546 - Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy Phase 1
Completed NCT00069004 - A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth N/A
Completed NCT00025883 - Leptin to Treat Lipodystrophy Phase 2
Completed NCT00001142 - Metabolism and Body Shape of Healthy Children and Children With Chronic Infections N/A
Active, not recruiting NCT02262806 - Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Phase 2
Completed NCT02258685 - Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
Completed NCT00192621 - Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Phase 4
Completed NCT00006190 - A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Phase 4
Recruiting NCT05930106 - Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management N/A
Completed NCT00004329 - Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy N/A
Recruiting NCT04656054 - Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
Completed NCT00082628 - Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients Phase 3
Withdrawn NCT01788462 - Egrifta Replacement and Sleep Disordered Breathing N/A